In vivo, ITGB2-AS1 inhibition reduces cisplatin resistance, indicating that ITGB2-AS1 promotes cisplatin resistance in NSCLC by blocking p53-mediated ferroptosis via the FOSL2/NAMPT pathway (Chen et al., 2023). Here, TP53 is linked to non-small cell lung carcinoma.